43 results on '"Piacentini, F"'
Search Results
2. Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era
3. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
4. The long duration cryogenic system of the OLIMPO balloon–borne experiment: Design and in–flight performance
5. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
6. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
7. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
8. COVID-related disruption in mammographic screening: a year later
9. Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
10. C50 - Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status
11. QUBIC: The QU bolometric interferometer for cosmology
12. 267P Pathological complete response after neoadjuvant chemotherapy plus pertuzumab and trastuzumab for HER2+ early breast cancer: Real-world data from NeoPowER study
13. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy
14. The Cosmic Microwave Background in the Light of Planck
15. CMB polarization with B oomerang 2003
16. The BRAIN CMB polarization experiment
17. Searching for non-Gaussian signals in the BOOMERanG 2003 CMB map: Preliminary results
18. The millimeter sky as seen with BOOMERanG
19. Observations of the temperature and polarization anisotropies with Boomerang 2003
20. 190P Staging strategies of newly diagnosed triple-negative breast cancer (TNBC): Comparison between CT scan and 18F-FDG-PET/CT
21. Measuring CMB polarization with B oomerang
22. BOOMERANG returns
23. The new images of the microwave sky: a concordance cosmology ?
24. 239P Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
25. 137P Survivorship care plan for breast cancer patients: An intensive follow-up is still useless?
26. 41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial
27. Mapping the CMB sky: THE BOOMERanG experiment
28. 19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study
29. 323P - Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials
30. 244P - Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
31. 207P - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study
32. 191PD_PR - 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
33. 337P - First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better?
34. 96P - ERBB2 and PI3KCA mutations in endocrine resistant breast cancer (BC)
35. 3* - Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
36. 272P - Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors
37. F55 - Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience
38. F48 - Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer
39. F31 - Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus
40. 57 - Soluble TRAIL-Armed Human AD-MSC as Novel Cell Therapy: Approach for Pancreatic Ductal Adenocarcinoma
41. 5149 Randomized phase II trial of preoperative chemotherapy plus lapatinib, trastuzumab or both in HER2 positive breast cancer: results of the first step simon's design
42. Foreword
43. Metabisulfite oral challenge: Incidence of adverse responses in chronic childhood asthma and its relationship with bronchial hyperreactivity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.